Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
PURE BiosciencePURE Debt-to-EBITDA is -3.14 as of Apr. 2026. The stock has 5 warning signs investors should review. Among 1,552 Consumer Packaged Goods companies, PURE Bioscience ranks worse than 64432.93% on this metric.
Debt-to-EBITDA measures a company's ability to pay off its debt.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
The historical rank and industry rank for PURE Bioscience's Debt-to-EBITDA or its related term are showing as below:
PURE'
s Debt-to-EBITDA Range Over the Past 10 Years
Min: -3.58 Med: -0.27 Max: -0.07
Current: -3.58
During the past 13 years, the highest Debt-to-EBITDA Ratio of PURE Bioscience was -0.07. The lowest was -3.58. And the median was -0.27.
PURE's Debt-to-EBITDA is ranked worse than 100% of 1552
companies
in the Consumer Packaged Goods industry
Industry Median: 2.065
vs PURE: -3.58
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
PURE Bioscience Debt-to-EBITDA Related Terms
PURE Bioscience Debt-to-EBITDA Historical Data
* Premium members only.
The historical data trend for PURE Bioscience's Debt-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
PURE vs DQWS, TANH, DSY: Debt-to-EBITDA Comparison
For the Household & Personal Products subindustry, PURE Bioscience's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
PURE Bioscience Debt-to-EBITDA vs Consumer Packaged Goods Industry
For the Consumer Packaged Goods industry and Consumer Defensive sector, PURE Bioscience's Debt-to-EBITDA distribution charts can be found below:
* The bar in red indicates where PURE Bioscience's Debt-to-EBITDA falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data,
the EBITDA data used here is four times the quarterly (Apr. 2026) EBITDA data.
PURE Bioscience (PURE) has a Debt-to-EBITDA of -3.14 as of Apr. 2026. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on PURE Bioscience. According to the industry distribution chart, PURE Bioscience ranks #999999 out of 1552 companies in the Consumer Packaged Goods industry.
Is PURE Bioscience's Debt-to-EBITDA too high?
PURE Bioscience's current Debt-to-EBITDA is -3.14. Based on the distribution chart, PURE Bioscience ranks #999999 out of 1552 companies in the Consumer Packaged Goods industry, which is in the bottom quartile relative to peers.
How does PURE Bioscience's Debt-to-EBITDA compare to DQWS and TANH?
According to the Consumer Packaged Goods industry distribution chart, PURE Bioscience ranks #999999 out of 1552 companies for Debt-to-EBITDA. This places PURE Bioscience in the lower half of its industry. The industry median Debt-to-EBITDA is 2.07. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-EBITDA for a Consumer Packaged Goods company?
The median Debt-to-EBITDA among Consumer Packaged Goods companies is 2.07, based on 1,552 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-EBITDA mean?
A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on PURE Bioscience. For the Consumer Packaged Goods industry, the median Debt-to-EBITDA is 2.07 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. PURE Bioscience's current Debt-to-EBITDA is -3.14. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is PURE Bioscience stock overvalued right now?
Based on GuruFocus' analysis, PURE Bioscience (PURE) is currently considered Possible Value Trap. The stock's GF Value™ is $0.10, compared to a current price of $0.07 — trading 35% below its estimated fair value. The current Debt-to-EBITDA is -3.14. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-EBITDA calculated?
Debt-to-EBITDA is calculated from a company's financial statements. For PURE Bioscience (PURE), the current Debt-to-EBITDA is -3.14 as of Apr. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
PURE Bioscience Inc is engaged in developing and commercializing proprietary antimicrobial products. The company's technology platform is based on patented stabilized ionic silver, and its initial products contain silver dihydrogen citrate, or SDC. It offers PURE Hard Surface as a food contact surface sanitizer and disinfectant to restaurant chains, food processors and food transportation companies and PURE Control as a direct food contact processing aid. It also manufactures and sells SDC-based products for end use, and products preserved with SDC and SDC as a raw material ingredient for manufacturing use. The company generates revenue from the sale of its antimicrobial products.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
PURE has been successfully added to your 
